125 related articles for article (PubMed ID: 15755280)
21. Prognostic Impact of WT-1 Gene Expression in Egyptian Children with Acute Lymphoblastic Leukemia.
Hagag AA; Badraia IM; Hassan SM; Abd El-Lateef AE
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016008. PubMed ID: 26740869
[TBL] [Abstract][Full Text] [Related]
22. Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.
Giraud M; Salson M; Duez M; Villenet C; Quief S; Caillault A; Grardel N; Roumier C; Preudhomme C; Figeac M
BMC Genomics; 2014 May; 15(1):409. PubMed ID: 24885090
[TBL] [Abstract][Full Text] [Related]
23. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.
Bar M; Wood BL; Radich JP; Doney KC; Woolfrey AE; Delaney C; Appelbaum FR; Gooley TA
Leuk Res Treatment; 2014; 2014():421723. PubMed ID: 24778882
[TBL] [Abstract][Full Text] [Related]
24. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
25. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia.
Weng XQ; Shen Y; Sheng Y; Chen B; Wang JH; Li JM; Mi JQ; Chen QS; Zhu YM; Jiang CL; Yan H; Zhang XX; Huang T; Zhu Z; Chen Z; Chen SJ
Blood Cancer J; 2013 Aug; 3(8):e133. PubMed ID: 23955588
[TBL] [Abstract][Full Text] [Related]
27. Measurements of treatment response in childhood acute leukemia.
Campana D; Coustan-Smith E
Korean J Hematol; 2012 Dec; 47(4):245-54. PubMed ID: 23320002
[TBL] [Abstract][Full Text] [Related]
28. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.
Gaipa G; Cazzaniga G; Valsecchi MG; Panzer-Grümayer R; Buldini B; Silvestri D; Karawajew L; Maglia O; Ratei R; Benetello A; Sala S; Schumich A; Schrauder A; Villa T; Veltroni M; Ludwig WD; Conter V; Schrappe M; Biondi A; Dworzak MN; Basso G
Haematologica; 2012 Oct; 97(10):1582-93. PubMed ID: 22581001
[TBL] [Abstract][Full Text] [Related]
29. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?
Campana D
Curr Hematol Malig Rep; 2012 Jun; 7(2):170-7. PubMed ID: 22373809
[TBL] [Abstract][Full Text] [Related]
30. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).
Asselin BL; Devidas M; Wang C; Pullen J; Borowitz MJ; Hutchison R; Lipshultz SE; Camitta BM
Blood; 2011 Jul; 118(4):874-83. PubMed ID: 21474675
[TBL] [Abstract][Full Text] [Related]
32. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.
Coustan-Smith E; Campana D
Best Pract Res Clin Haematol; 2010 Sep; 23(3):347-58. PubMed ID: 21112034
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
Kikuchi M; Tanaka J; Kondo T; Hashino S; Kasai M; Kurosawa M; Iwasaki H; Morioka M; Kawamura T; Masauzi N; Fukuhara T; Kakinoki Y; Kobayashi H; Noto S; Asaka M; Imamura M
Int J Hematol; 2010 Oct; 92(3):481-9. PubMed ID: 20830615
[TBL] [Abstract][Full Text] [Related]
34. Progress of minimal residual disease studies in childhood acute leukemia.
Campana D
Curr Hematol Malig Rep; 2010 Jul; 5(3):169-76. PubMed ID: 20467922
[TBL] [Abstract][Full Text] [Related]
35. Role of minimal residual disease evaluation in leukemia therapy.
Campana D
Curr Hematol Malig Rep; 2008 Jul; 3(3):155-60. PubMed ID: 20425460
[TBL] [Abstract][Full Text] [Related]
36. New approaches for the detection of minimal residual disease in acute myeloid leukemia.
van Rhenen A; Moshaver B; Ossenkoppele GJ; Schuurhuis GJ
Curr Hematol Malig Rep; 2007 May; 2(2):111-8. PubMed ID: 20425359
[TBL] [Abstract][Full Text] [Related]
37. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.
Elorza I; Palacio C; Dapena JL; Gallur L; Sánchez de Toledo J; Díaz de Heredia C
Haematologica; 2010 Jun; 95(6):936-41. PubMed ID: 20179088
[TBL] [Abstract][Full Text] [Related]
38. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.
Campana D
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1083-98, vii. PubMed ID: 19825454
[TBL] [Abstract][Full Text] [Related]
39. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
Béné MC; Kaeda JS
Haematologica; 2009 Aug; 94(8):1135-50. PubMed ID: 19586938
[TBL] [Abstract][Full Text] [Related]
40. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
